Survival trends in patients with difficult-to-treat, antibiotic-resistant, Gram-negative infections in the era of next-generation antibiotics in the USA: a retrospective cohort study - PubMed
8 hours ago
- #retrospective study
- #antibiotic resistance
- #gram-negative infections
- The study examined survival trends in US patients with difficult-to-treat resistant (DTR) Gram-negative infections from 2016 to 2023, during the introduction of next-generation antibiotics.
- DTR infections are resistant to first-line antibiotics and associated with a 40% higher mortality rate compared to susceptible infections.
- Despite increased availability and prescription of newer DTR-active antibiotics, in-hospital mortality rates did not significantly change overall for most pathogens, except for Pseudomonas aeruginosa bloodstream infections, which showed a decrease.
- A key finding is that even in 2023, most patients (84%) with DTR infections continued to receive in-vitro discordant initial antibiotic therapy, meaning the antibiotics used were not effective against the pathogen based on lab tests.
- The study suggests that prompt recognition of pathogens and their resistance profiles is crucial to reduce mortality, highlighting ongoing challenges in managing DTR infections despite new treatment options.